title: Antitumour activity of cationic-liposome-conjugated adenovirus containing the CCL19 [chemokine (C-C motif) ligand 19] gene.
abstract: CCL19 [chemokine (C-C motif) ligand 19; also known as MIP-3beta (macrophage inflammatory protein-3beta) or ELC (Epstein-Barr-virus-induced molecule 1 ligand chemokine)], one of the immunostimulatory cytokines, chemoattracts both DCs (dendritic cells) and T-lymphocytes. Adenoviral vector is one of the most used gene delivery vectors for cancer therapy because of its high gene-transfection efficiency. However, its wider application is limited, owing to immune responses that reduce transgene expression and decrease the efficacy of repeated administration. We constructed the recombinant replication deficient adenoviral vectors containing the CCL19 gene (Ad-CCL19) and combined them with PEG-PE [poly(ethylene glycol)-phosphatidylethanolamine]-modified cationic liposomes (Ad-CCL19/PEG-PE) for immunotherapy against murine fibrosarcoma. Although there were hardly any therapeutic differences between Ad-CCL19- and Ad-CCL19/PEG-PE-treated mice that were observed at the second administration, the final results demonstrated that Ad-CCL19/PEG-PE-treated mice survived much longer. The antitumour efficacy may be related to the high level of CCL19 after the final administration and lasting expression of IFN-gamma (interferon-gamma) and IL-12 (interleukin-12) in the Ad-CCL19/PEG-PE-treated group, which were measured by reverse-transcription PCR and ELISA. The results demonstrated that PEG-PE-cationic-liposome-conjugated adenovirus could prolong the expression of the therapeutic gene in vivo and may enhance the antitumour efficacy.
authors.affiliation: Key Laboratory of Biological Resource and Ecological Environment of the Ministry of Education, College of Life Science, Sichuan University, Chengdu 610064, People's Republic of China.
authors.forename: Mei
authors.initials: M
authors.lastname: Cao
authors.forename: Hong-Xin
authors.initials: HX
authors.lastname: Deng
authors.forename: Jian
authors.initials: J
authors.lastname: Zhao
authors.forename: Lin-yu
authors.initials: LY
authors.lastname: Fan
authors.forename: Yu
authors.initials: Y
authors.lastname: Jiang
authors.forename: Yan-Jun
authors.initials: YJ
authors.lastname: Wen
authors.forename: Jiong
authors.initials: J
authors.lastname: Li
authors.forename: Song
authors.initials: S
authors.lastname: Lei
authors.forename: Yong-qiu
authors.initials: YQ
authors.lastname: Mao
authors.forename: Zhen-Yu
authors.initials: ZY
authors.lastname: Ding
authors.forename: Yu-quan
authors.initials: YQ
authors.lastname: Wei
mesh_terms: D000256:Adenoviridae / Q000737:chemistry / Q000235:genetics*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002412:Cations; D054415:Chemokine CCL19; D019742:Chemokines, CC / Q000235:genetics* / Q000627:therapeutic use*; D005260:Female; D018390:Gene Targeting / Q000379:methods*; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics; D008081:Liposomes / Q000737:chemistry*; D008175:Lung Neoplasms / Q000235:genetics / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D014162:Transfection / Q000379:methods; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D002412:Cations; C515461:Ccl19 protein, mouse; D054415:Chemokine CCL19; D019742:Chemokines, CC; D008081:Liposomes